- Report
- April 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- January 2022
- 112 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2023
- 240 Pages
Global
From €3378EUR$3,500USD£2,898GBP
- Report
- August 2022
- 155 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- August 2022
- 161 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- February 2018
- 15 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Drug Pipelines
- February 2018
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- February 2018
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- April 2023
- 156 Pages
Global
€4826EUR$5,000USD£4,140GBP
- Report
- April 2023
- 114 Pages
Global
€3378EUR$3,500USD£2,898GBP
- Report
- April 2023
- 109 Pages
Global
€3378EUR$3,500USD£2,898GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,884USD£3,107GBP
Mometasone is a corticosteroid drug used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is available in both topical and inhaled forms, and is used to reduce inflammation in the airways. It is often prescribed in combination with other drugs, such as bronchodilators, to provide more comprehensive relief. Mometasone is generally well-tolerated, but can cause side effects such as headaches, nausea, and throat irritation.
The mometasone market is a subset of the larger respiratory drugs market, which includes a variety of treatments for respiratory conditions. The market is highly competitive, with a number of major pharmaceutical companies offering mometasone-based products. These include GlaxoSmithKline, Merck, Novartis, and Pfizer. Generic versions of mometasone are also available, providing an affordable alternative for patients. Show Less Read more